Previous Close | 13.55 |
Open | 13.55 |
Bid | 13.17 x 900 |
Ask | 13.47 x 1000 |
Day's Range | 13.03 - 13.55 |
52 Week Range | 5.69 - 15.50 |
Volume | 33,720 |
Avg. Volume | 352,086 |
Market Cap | 282.038M |
Beta (5Y Monthly) | 0.11 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.74 |
Earnings Date | Nov 12, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.67 |
Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that it has selected RESONICâ„¢ as the brand name for the Rapid Acoustic Pulse (RAP) Device.
Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary aesthetic platform technology, today announced that a pre-clinical study in animals demonstrated positive results for the potential treatment of liver fibrosis. Validated laboratory and histological assessments in a mouse model demonstrated that Rapid Acoustic Pulse ("RAP") therapy reduced the effects of induced liver fibrosis 7-days following completion of carbon tetrachloride (CCL4) induction by 42%. In addition, post treatment histology slides stained with picrosirius red (PSR) showed a lower percentage of fibrosis from a single 2-minute RAP treatment compared to the Control group.
Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that the Company is scheduled to release its fourth quarter and full year 2020 financial results on Thursday, March 4, 2021, after the market closes.